Core Viewpoint - Midea Medical's stock has experienced fluctuations, with a year-to-date increase of 41.57% but a recent decline in the last 5, 20, and 60 trading days [1] Financial Performance - For the period from January to September 2025, Midea Medical achieved a revenue of 225 million yuan, representing a year-on-year growth of 2.31% [2] - The net profit attributable to the parent company was 8.84 million yuan, showing a year-on-year increase of 15.82% [2] Stock Market Activity - As of December 2, Midea Medical's stock price was 15.29 yuan per share, with a market capitalization of 2.54 billion yuan [1] - The stock has seen a net inflow of 353,400 yuan from main funds, with a significant portion of buying activity [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the last occurrence on August 26, where it recorded a net buy of -57.70 million yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 4,528, while the average circulating shares per person decreased by 15.97% to 36,709 shares [2] - The top ten circulating shareholders include notable funds, with some new entrants and exits among them [3] Dividend Distribution - Midea Medical has distributed a total of 202 million yuan in dividends since its A-share listing, with 99.30 million yuan distributed over the past three years [3] Business Overview - Midea Medical, established in March 2003 and listed in December 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main revenue sources are safety infusion products (48.75%), blood purification products (26.27%), and other products (24.98%) [1]

Core Viewpoint - As of November 28, 2025, Maide Medical (688310) closed at 16.03 yuan, down 4.53%, with a turnover rate of 4.12% and a trading volume of 68,500 hands, resulting in a transaction amount of 110 million yuan [1] Financial Performance - For the first three quarters of 2025, the company's main revenue was 225 million yuan, an increase of 2.31% year-on-year; the net profit attributable to the parent company was 8.84 million yuan, up 15.82% year-on-year; the non-recurring net profit was -1.28 million yuan, a decrease of 526.58% year-on-year [5] - In Q3 2025, the company's single-quarter main revenue was 83.64 million yuan, an increase of 54.38% year-on-year; the single-quarter net profit attributable to the parent company was 2.79 million yuan, up 224.07% year-on-year; the single-quarter non-recurring net profit was 1.24 million yuan, an increase of 118.23% year-on-year [5] Market Position and Ratios - Maide Medical's total market value is 2.665 billion yuan, with a net asset of 840 million yuan and a net profit of 8.84 million yuan [3] - The company's price-to-earnings ratio (P/E) is 226.15, while the industry average is 130.51; the price-to-book ratio (P/B) is 3.31, compared to the industry average of 4.59 [3] - The gross profit margin is 40.19%, significantly higher than the industry average of 27.79%, while the net profit margin is -2.43%, lower than the industry average of 4.37% [3] Capital Flow - On November 28, 2025, the net inflow of main funds was 14.26 million yuan, accounting for 13.01% of the total transaction amount; the net inflow of retail funds was 1.73 million yuan, accounting for 15.83% of the total transaction amount [1] - In terms of margin trading, the financing buy amounted to 19.92 million yuan, with a net buy of 12.48 million yuan, while there were no securities sold or repaid [2]

Core Viewpoint - Midea Medical's stock price dropped by 5% to 15.95 CNY per share, with a total market capitalization of 2.651 billion CNY as of the report date [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019 [1] - The company's main business involves the research, production, sales, and service of medical consumables and intelligent equipment [1] - Revenue composition: Safety infusion products account for 48.75%, blood purification products 26.27%, and other products 24.98% [1] Shareholder Information - Among the top ten circulating shareholders, one fund from Huaxia Fund holds shares in Midea Medical [2] - Huaxia Industry Prosperity Mixed A (003567) reduced its holdings by 1.0661 million shares in Q3, now holding 2.6036 million shares, representing 1.57% of circulating shares [2] - Estimated floating loss for Huaxia Industry Prosperity Mixed A today is approximately 2.187 million CNY [2] Fund Manager Details - The fund manager of Huaxia Industry Prosperity Mixed A is Zhong Shuai [3] - As of the report date, Zhong Shuai has a cumulative tenure of 5 years and 125 days, with total fund assets of 13.26 billion CNY [3] - Best fund return during tenure is 169.98%, while the worst return is -5.09% [3]

2、提议时间：2025年11月27日 二、提议人提议回购股份的原因和目的 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 迈得医疗工业设备股份有限公司（以下简称"公司"或"迈得医疗"）于2025年11月27日收到公司董事长、 实际控制人林军华先生《关于提议迈得医疗工业设备股份有限公司回购公司股份的函》，具体内容如 下： 一、提议人的基本情况及提议时间 1、提议人：公司董事长、实际控制人林军华先生 四、提议人在提议前6个月内买卖本公司股份的情况 基于对公司未来发展的信心和对公司价值的认可，为有效维护广大股东利益，增强投资者信心，在综合 考虑公司财务状况以及未来盈利能力的情况下，公司董事长、实际控制人林军华先生提议公司以首次公 开发行股票超募资金或自有资金回购部分公司股份，用于减少公司注册资本。 三、提议人的提议内容 1、回购股份的种类：公司发行的人民币普通股（A股）。 2、回购股份的用途：用于减少公司注册资本。 3、回购股份的方式：集中竞价交易方式。 4、回购股份的价格：不高 ...

Group 1 - Tianpu Co., Ltd. has experienced significant stock price volatility, with a cumulative increase of 451.80% from August 22, 2025, to November 27, 2025, leading to a suspension of trading for verification starting November 28, 2025 [1] Group 2 - FAW Jiefang plans to increase capital in its joint venture, Jiefang Times, by 191 million yuan, with a total capital increase of 412 million yuan alongside CATL and new investor Telepower, enhancing competitiveness in the new energy commercial vehicle sector [2] Group 3 - Qingdao Beer plans to invest in low-risk financial products with a maximum daily balance of 10 billion yuan over the next 12 months to improve fund efficiency and returns for shareholders [3] - Haohan Deep plans to acquire a 16.0656% stake in Guorui Smart for 70.68864 million yuan, increasing its ownership to 51.0656% [3] Group 4 - Huazhi Jie intends to invest 100 million yuan to establish Suzhou Kangyang Robot Co., Ltd., aligning with its strategic development plans [4] - Maide Medical's chairman proposes a share buyback of 20 million to 40 million yuan to reduce registered capital [4] Group 5 - Haichang New Materials plans to acquire 51% of Shenzhen Xinwei Communication Technology Co., Ltd. for 23.46 million yuan, gaining control over the company [5] - Hunan Gold's subsidiary obtained a mining license for a tungsten mine with an annual production capacity of 990,000 tons [5] Group 6 - Tianli Lithium Energy received two invention patents related to lithium-ion battery electrode materials, enhancing its core technology and competitive edge [6] Group 7 - Changan Automobile's indirect controlling shareholder underwent a restructuring, resulting in a new entity, China Changan Automobile Group, which holds 35.04% of Changan Automobile's shares [7] Group 8 - *ST Lian Shi's stock will resume trading on November 28, 2025, following a capital reserve increase [8] - Jia You International signed a strategic cooperation memorandum with the China-Africa Development Fund, expected to positively impact business development [8] Group 9 - China Aluminum International's subsidiary won a contract for a project worth 2.9086858 billion yuan, which could enhance the company's operational scale and profitability [9] Group 10 - Guizhou Sanli changed its stock abbreviation to "Sanli Pharmaceutical," while maintaining its full name and stock code [10] - China CRRC plans to spin off its subsidiary, CRRC Qichu, for listing on the Shenzhen Stock Exchange, retaining control over the subsidiary [10] Group 11 - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on integrated circuit-related sectors [11] - Huiyu Pharmaceutical intends to co-invest in a biomedical venture capital fund with a total initial subscription of 400 million yuan [11] Group 12 - Everbright Bank received notification of a shareholding increase by CITIC Financial Asset Management, raising its stake from 8.00% to 9.00% [12] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan within six months [12][13]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-049 迈得医疗工业设备股份有限公司 关于公司董事长、实际控制人提议公司回购股份的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈得医疗工业设备股份有限公司（以下简称"公司"或"迈得医疗"）于2025年 11月27日收到公司董事长、实际控制人林军华先生《关于提议迈得医疗工业设备 股份有限公司回购公司股份的函》，具体内容如下： 一、 提议人的基本情况及提议时间 1、提议人：公司董事长、实际控制人林军华先生 2、提议时间：2025年11月27日 二、 提议人提议回购股份的原因和目的 基于对公司未来发展的信心和对公司价值的认可，为有效维护广大股东利益， 增强投资者信心，在综合考虑公司财务状况以及未来盈利能力的情况下，公司董 事长、实际控制人林军华先生提议公司以首次公开发行股票超募资金或自有资金 回购部分公司股份，用于减少公司注册资本。 三、 提议人的提议内容 1、 回购股份的种类：公司发行的人民币普通股（A股）。 2、 回购股份的用途：用于减少公司注册资本 ...

Summary of Key Points Core Viewpoint - On November 27, several A-share listed companies disclosed their shareholding changes, with notable increases in holdings from some companies and reductions from others, indicating varying levels of confidence among stakeholders in the market [1]. Group 1: Shareholding Increases - Mindray Medical's actual controller and chairman, Li Xiting, plans to increase his stake in the company by 200 million yuan [2]. - Everbright Bank saw Citic Financial Assets increase its holdings in both A-shares and H-shares by a total of 1% from July 24 to November 27 [2]. - MaiDe Medical's chairman and actual controller, Lin Junhua, proposed a share buyback plan ranging from 20 million to 40 million yuan [2]. Group 2: Shareholding Reductions - Yonghe Intelligent Control's shareholders plan to collectively reduce their holdings by no more than 3.29% [2]. - Perfect World’s actual controller, Chi Yufeng, intends to reduce his stake by no more than 1.70% [2]. - XueNeng Technology's shareholder, Shanghang Xingyuan, plans to reduce holdings by no more than 1.6816% [2]. - Hongxiang New Materials' controlling shareholder, Hongbo Chemical, has cumulatively reduced its stake by 3% recently [2]. - Nearshore Protein's shareholders plan to collectively reduce their holdings by no more than 0.1997% [2]. - Aerospace Hongtu's director and executive, Huang Yongbo, plans to reduce his stake by no more than 0.0019% [2]. - Yidelong's shareholder, Wang Ming, intends to reduce his holdings by no more than 2% [2]. - Zhongman Petroleum's shareholders plan to collectively reduce their holdings by no more than 3% [2]. - Innovation New Materials' shareholder, Hualian Group, plans to reduce its stake by no more than 1% [2]. - Saiwei Electronics has seen the National Integrated Circuit Industry Investment Fund reduce its holdings by 6.4278 million shares [2]. - Zhongzhi Technology's shareholder, Zhongzhi Investment, plans to reduce its stake by no more than 0.76% [2]. - Jiangsu Boyun's shareholder, Lansan Venture Capital, intends to reduce its holdings by no more than 1% [2]. - Huasheng Lithium's deputy general manager, Zhang Conghe, plans to reduce his stake by no more than 0.31% [2]. - Huasheng Electric's shareholder, Dunxing Jucai, reduced its holdings by 444,500 shares between November 25 and 27 [2]. - Matrix Technology's shareholder, Li Jun, plans to reduce his stake by no more than 0.22% [2].

Major Announcements - Glacier Network plans to sign an exclusive overseas agency agreement with Chengdu Time Race Technology Co., Ltd., a 14% owned affiliate, for the promotion and operation of "Magic War" [3] - Nairui Radar intends to acquire 100% equity of Tianjin Sigma Microelectronics Technology Co., Ltd. through a combination of share issuance and cash payment [4] - Howie Group's wholly-owned subsidiary, Shaoxing Wehao, plans to invest 200 million yuan in a private equity fund, holding an 18.39% stake [5] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [6] - Yanzhou Coal Mining plans to acquire 100% equity of a high-end support manufacturing company for 345 million yuan, constituting a related party transaction [7] Termination of Cooperation - Jincheng Pharmaceutical has decided to terminate its intention to cooperate with Dutch company Giskit regarding the exclusive commercialization rights of ExEm® Foam in China due to lack of substantial progress in negotiations [9] Mining License Acquisition - Hunan Gold's subsidiary Xinshao Siwei has obtained a mining license for the Xinshao County Tanxi Tungsten Mine, with an annual production capacity of 990,000 tons [10] Share Buybacks - Visionox has initiated a share buyback of 1.6607 million shares for approximately 15 million yuan, with a maximum price of 14.8 yuan per share [11] - Koli completed a share buyback amounting to 10.9949 million yuan, acquiring 845,700 shares at prices between 12.89 and 13.13 yuan per share [12] - Maide Medical's chairman proposed a share buyback plan with a total amount between 20 million and 40 million yuan [13] Shareholding Changes - Funeng Technology's shareholder plans to reduce its stake by up to 1.6816%, totaling no more than 20.551 million shares [14] - Aerospace Hongtu's director intends to sell up to 5,000 shares due to personal financial needs [15] Project Wins - Anhui Construction has won two projects with a total bid price of 2.603 billion yuan, with the company's share being approximately 600 million yuan [16][17]

Major Events - Glacier Network plans to sign an exclusive overseas agency agreement with Chengdu Time Race Technology Co., Ltd., a company in which it holds a 14% stake, for the promotion and operation of "Magic War" [4] - Nairui Radar intends to acquire 100% equity of Tianjin Sigma Microelectronics Technology Co., Ltd. through a combination of issuing shares and cash [5] - Howey Group's wholly-owned subsidiary, Shaoxing Wehao, plans to invest 200 million yuan in a private equity fund [6][7] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [8] - Yanzhou Coal Mining plans to acquire 100% equity of a high-end support manufacturing company for 345 million yuan, constituting a related party transaction [9] - Jincheng Pharmaceutical has decided to terminate its intention to cooperate with Dutch company Giskit regarding exclusive commercialization rights for a drug in China due to lack of substantial progress [10] - Hunan Gold's subsidiary obtained a mining license for tungsten, magnetite, and silver with an annual production capacity of 990,000 tons [11] Share Buybacks - Visionox completed its first share buyback of 1.6607 million shares for approximately 15 million yuan, with a maximum price of 14.8 yuan per share [12] - Koli completed a share buyback of 10.9949 million yuan, acquiring 845,700 shares at prices between 12.89 and 13.13 yuan per share [13][14] - Maide Medical's chairman proposed a share buyback plan with a total amount between 20 million and 40 million yuan [15] Shareholding Changes - Funeng Technology's shareholder plans to reduce its stake by up to 1.6816%, totaling approximately 20.551 million shares [16] - Aerospace Hongtu's director plans to reduce his holdings by 5,000 shares due to personal financial needs [17] Major Contracts - Anhui Construction won two projects with a total bid price of 2.603 billion yuan, with the company's share being approximately 600 million yuan for each project [18]

Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]